Table 2 Baseline values of eicosanoids in patients with AIA or ATA and healthy controls (values represent means of three estimations performed in each patient 1 week apart)

	AIA (n = 19)	ATA (n = 21)	Healthy (n = 30)	p Value
	AIA (n = 19)	ATA (n = 21)	Healthy (n = 30)	AIA vs ATA	AIA vs HC	ATA vs HC
Urinary PGE₂-M (pg/mg creatinine)	477.1 (277.69)	480.7 (222.1)	879.47 (210.78)	0.95	0.88	0.72
Urinary PGE₂-M (pg/mg creatinine)	464 (281–600)	451 (342–538)	403.5 (303–763)	0.95	0.88	0.72
Urinary tetranor-PGE-M (ng/mg creatinine)	11.05 (9.64)	10.27 (7.83)	10.06 (8.43)	0.79	0.96	0.87
Urinary tetranor-PGE-M (ng/mg creatinine)	7.2 (5.4–11.1)	7.9 (5.0–12.4)	7.6 (4.9–10.5)	0.79	0.96	0.87
Urinary LTE₄ (pg/mg creatinine)	1846.6 (2747.4)	342.0 (277.7)	257.0 (180.2)	<0.001	<0.001	0.75
Urinary LTE₄ (pg/mg creatinine)	1347 (355–2036)	220 (160–361)	222 (119–315)	<0.001	<0.001	0.75

Values are expressed as mean (SD) and median (25–75% percentiles).
AIA, aspirin-induced asthma; ATA, aspirin-tolerant asthma; PGE₂-M, 13,14-dihydro-15keto-PGE₂; tetranor-PGE-M, 9,15-dioxo-11α-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid; LTE₄, leucotriene E₄.